Literature DB >> 21350940

Doxepin concentrations in plasma and cerebrospinal fluid.

Robert Schomburg1, Daniela Remane, Klaus Fassbender, Hans H Maurer, Jörg Spiegel.   

Abstract

Doxepin--like other antidepressant drugs (ADs)--shows a variable antidepressant effect in clinical practice. The cause for this variability is as yet unclear; however, pharmacokinetic factors such as the variable permeability of doxepin into the cerebrospinal fluid (CSF), may contribute to the difference in therapeutic efficacy. We measured and correlated the concentration of doxepin and its active metabolite nordoxepin in both the plasma and CSF. Plasma and CSF samples were taken simultaneously from 21 patients who were treated with doxepin due to different clinical indications. The plasma concentration of both doxepin and nordoxepin correlated significantly with the oral dosage of doxepin (doxepin: r = +0.66, p < 0.001; nordoxepin: r = +0.78, p < 0.0001; Spearman's correlation). Furthermore, we found significant correlations between the plasma and CSF concentrations of both doxepin (r = +0.71; p < 0.001; Pearson's correlation) and nordoxepin (r = +0.74; p < 0.001). These highly significant correlations between the plasma and CSF concentrations indicate a constant CSF permeability of doxepin and its active metabolite nordoxepin.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21350940     DOI: 10.1007/s00702-011-0613-x

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  13 in total

Review 1.  Detoxification systems, passive and specific transport for drugs at the blood-CSF barrier in normal and pathological situations.

Authors:  Nathalie Strazielle; Seng T Khuth; Jean-François Ghersi-Egea
Journal:  Adv Drug Deliv Rev       Date:  2004-10-14       Impact factor: 15.470

2.  Relationship between dopamine D2 receptor occupancy, clinical response, and drug and monoamine metabolites levels in plasma and cerebrospinal fluid. A pilot study in patients suffering from first-episode schizophrenia treated with quetiapine.

Authors:  Georg Nikisch; Pierre Baumann; Bernhard Kiessling; Michael Reinert; Georg Wiedemann; Jan Kehr; Aleksander A Mathé; Markus Piel; Frank Roesch; Heike Weisser; Peter Schneider; Andreas Hertel
Journal:  J Psychiatr Res       Date:  2010-02-21       Impact factor: 4.791

Review 3.  The choroid plexus-cerebrospinal fluid system: from development to aging.

Authors:  Zoran B Redzic; Jane E Preston; John A Duncan; Adam Chodobski; Joanna Szmydynger-Chodobska
Journal:  Curr Top Dev Biol       Date:  2005       Impact factor: 4.897

4.  Doxepin and its metabolites in plasma and cerebrospinal fluid in depressed patients.

Authors:  M Deuschle; S Härtter; C Hiemke; H Standhardt; I Heuser
Journal:  Psychopharmacology (Berl)       Date:  1997-05       Impact factor: 4.530

5.  Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF.

Authors:  Georg Nikisch; Pierre Baumann; Georg Wiedemann; Bernhard Kiessling; Heike Weisser; Andreas Hertel; Takashi Yoshitake; Jan Kehr; Aleksander A Mathé
Journal:  J Clin Psychopharmacol       Date:  2010-10       Impact factor: 3.153

Review 6.  Clinical pharmacokinetics of cerebrospinal fluid.

Authors:  M Bonati; J Kanto; G Tognoni
Journal:  Clin Pharmacokinet       Date:  1982 Jul-Aug       Impact factor: 6.447

7.  Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study.

Authors:  Georg Nikisch; Pierre Baumann; Beatrice Oneda; Bernhard Kiessling; Heike Weisser; Aleksander A Mathé; Takashi Yoshitake; Jan Kehr; Georg Wiedemann; Chin B Eap
Journal:  J Psychopharmacol       Date:  2010-12-08       Impact factor: 4.153

8.  Mirtazapine enantiomers in blood and cerebrospinal fluid.

Authors:  Pierre Baumann; Michèle Jonzier-Perey; Erik Paus; Georg Nikisch
Journal:  Neuropsychobiology       Date:  2006-01-17       Impact factor: 2.328

9.  Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study.

Authors:  Georg Nikisch; Chin B Eap; Pierre Baumann
Journal:  Pharmacol Res       Date:  2008-09-30       Impact factor: 7.658

10.  CSF and plasma levels of nortriptyline and its 10-hydroxy metabolite.

Authors:  C Nordin; L Bertilsson; B Siwers
Journal:  Br J Clin Pharmacol       Date:  1985-10       Impact factor: 4.335

View more
  1 in total

1.  Distribution pattern of mirtazapine and normirtazapine in blood and CSF.

Authors:  Michael Paulzen; Gerhard Gründer; Simone C Tauber; Tanja Veselinovic; Christoph Hiemke; Sarah E Groppe
Journal:  Psychopharmacology (Berl)       Date:  2014-08-23       Impact factor: 4.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.